UK-based Oxford Endovascular Awarded Third Prize in EIT Health European Health Catapult (MedTech)

The UK-Ireland CLC congratulates Oxford Endovascular on their 3rd place award in the European Health Catapult (MedTech)

The final of the European Health Catapult, which took place at the EIT Health Summit, saw a cohort of exceptional start-ups/SMEs pitching in front of a panel of investors and experts. Amongst the four UK-Ireland based competitors, Oxford Endovascular was awarded the third prize in the MedTech category of the European Health Catapult.

Oxford Endovascular is in its final stage of development of a unique flow-diverter (OXIFLOW) for the minimally invasive treatment of intracranial aneurysms.

Oxiflow is a novel, next generation ‘flow-diverter’ that diverts blood flow away from intracranial aneurysms at risk of rupture. The device is a metallic mesh tube, laser cut from Nitinol (a Nickel Titanium Alloy), and can be placed more accurately and safely than existing products. Conforming to various blood vessel shapes, it reduces the risk of complications and enables the treatment of more patients. A human clinical trial is expected to commence in 2018 followed by CE marking approval and early commercialisation by 2021.

Oxford Endovascular Limited is a spin out from The University of Oxford launched in December 2015, led by CEO Mike Karim and Chairman Brian Howlett, two highly experienced specialists in the commercialisation of medical devices. We as a CLC are committed to support entrepreneurs / SMEs beyond their participation to EIT Health programmes and we hope that partners will select them for innovation projects.

You can read more about Oxford Endovascular and the other EIT Health UK-Ireland entrepreneurs in ‘Our Entrepreneurs’ brochure here.